Skip to main content

Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents

By Reuters  
   November 23, 2021

Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

Full story


Get the latest on healthcare leadership in your inbox.